These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22496617)

  • 1. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.
    Reiner T; Lacy J; Keliher EJ; Yang KS; Ullal A; Kohler RH; Vinegoni C; Weissleder R
    Neoplasia; 2012 Mar; 14(3):169-77. PubMed ID: 22496617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An
    Zmuda F; Blair A; Liuzzi MC; Malviya G; Chalmers AJ; Lewis D; Sutherland A; Pimlott SL
    J Med Chem; 2018 May; 61(9):4103-4114. PubMed ID: 29630818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
    Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.
    Reiner T; Keliher EJ; Earley S; Marinelli B; Weissleder R
    Angew Chem Int Ed Engl; 2011 Feb; 50(8):1922-5. PubMed ID: 21328671
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
    Zmuda F; Malviya G; Blair A; Boyd M; Chalmers AJ; Sutherland A; Pimlott SL
    J Med Chem; 2015 Nov; 58(21):8683-93. PubMed ID: 26469301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
    Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
    Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Imaging of PARP Expression Using
    Wilson TC; Xavier MA; Knight J; Verhoog S; Torres JB; Mosley M; Hopkins SL; Wallington S; Allen PD; Kersemans V; Hueting R; Smart S; Gouverneur V; Cornelissen B
    J Nucl Med; 2019 Apr; 60(4):504-510. PubMed ID: 30389822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
    Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
    Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-mediated measurement of target-drug binding in cancer cells.
    Ullal AV; Reiner T; Yang KS; Gorbatov R; Min C; Issadore D; Lee H; Weissleder R
    ACS Nano; 2011 Nov; 5(11):9216-24. PubMed ID: 21962084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma.
    Li D; Hu C; Yang J; Liao Y; Chen Y; Fu SZ; Wu JB
    Int J Nanomedicine; 2020; 15():10045-10058. PubMed ID: 33328733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioorthogonal small-molecule ligands for PARP1 imaging in living cells.
    Reiner T; Earley S; Turetsky A; Weissleder R
    Chembiochem; 2010 Nov; 11(17):2374-7. PubMed ID: 20967817
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.
    Huang T; Hu P; Banizs AB; He J
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3472-3476. PubMed ID: 28587822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
    Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
    Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.